Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002050167-25-000004
Filing Date
2025-09-24
Accepted
2025-09-24 16:26:54
Documents
1
Period of Report
2025-09-22

Document Format Files

Seq Description Document Type Size
1 form4-09242025_080950.html 4  
1 form4-09242025_080950.xml 4 4329
  Complete submission text file 0002050167-25-000004.txt   5834
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Issuer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address
Dandekar Atul (Reporting) CIK: 0002050167 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-42490 | Film No.: 251338770